z-logo
Premium
Tolerance and beta‐adrenergic blocking activity of flestolol, a short‐acting beta blocker
Author(s) -
Turlapaty Prasad,
Burge Judith,
Hulse James,
Achari Ramanuj,
Bell Valerie,
Mosberg Hans,
Laddu Atul
Publication year - 1986
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1986.93
Subject(s) - blockade , tachycardia , medicine , pharmacology , blood pressure , beta (programming language) , anesthesia , receptor , computer science , programming language
The tolerance and β‐adrenergic blocking activity of flestolol, a short‐acting β‐blocker, was investigated in 30 subjects. Flestolol infused intravenously at doses up to 100 μg/kg/min was found to be well tolerated. A dose‐dependent attenuation of isoproterenol‐induced tachycardia and increase in systolic blood pressure occurred with flestolol at doses ranging from 0.5 to 15.0 μg/kg/min. The average percent reduction in isoproterenol‐induced tachycardia (β‐blockade) at each dose of flestolol, 0.5, 2.5, 5.0, 15.0, and 50.0 μg/ kg/min, was 15.1%, 45.9%, 67.0%, 85.9%, and 90.3%, respectively. The onset of β‐blockade occurred within 30 minutes. After the end of flestolol infusion there was a marked reduction in β‐blockade within 6 minutes, with complete recovery from β‐blockade within 30 to 45 minutes. There was a statistically significant (P < 0.01) positive correlation between flestolol dosage and its blood levels (r = 0.91) as well as between the flestolol‐induced β‐blockade and its dosage (r = 0.62). Clinical Pharmacology and Therapeutics (1986) 39, 543–549; doi: 10.1038/clpt.1986.93

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom